---
input_text: "Expert consensus on the management of infusion-related reactions (IRRs)
  in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA
  modified Delphi panel. Crizanlizumab, a monoclonal antibody against P-selectin,
  has been shown to reduce vaso-occlusive crises (VOCs) compared to placebo in patients
  >= 16 years with sickle cell disease (SCD). However, there have been rare reports
  of patients experiencing severe pain and subsequent complications within 24 hours
  of crizanlizumab infusions. These events are defined as infusion-related reactions
  (IRRs). Informed by current literature and clinical experience, a group of content
  experts developed clinical guidelines for the management of IRRs in patients with
  SCD. We used the RAND/University of California, Los Angeles (UCLA) modified Delphi
  panel method, a valid, reproducible technique for achieving consensus. We present
  our recommendations for managing IRRs, which depend on patient characteristics including:
  prior history of IRRs to other monoclonal antibodies or medications, changes to
  crizanlizumab infusion rate and patient monitoring, pain severity relative to patient's
  typical SCD crises, and severe allergic symptoms. These recommendations outline
  how to evaluate and manage IRRs in patients receiving crizanlizumab. Future research
  should validate this guidance using clinical data and identify patients at risk
  for these IRRs."
raw_completion_output: |-
  primary_disease: sickle cell disease (SCD)
  medical_actions: evaluation of patient's prior history of IRRs to other monoclonal antibodies or medications; changes to crizanlizumab infusion rate; patient monitoring; management of pain; management of severe allergic symptoms
  symptoms: severe pain; severe allergic symptoms
  chemicals: crizanlizumab
  action_annotation_relationships: evaluation of patient's prior history of IRRs to other monoclonal antibodies or medications PREVENTS severe allergic symptoms IN sickle cell disease (SCD); changes to crizanlizumab infusion rate PREVENTS severe pain IN sickle cell disease (SCD); changes to crizanlizumab infusion rate PREVENTS severe allergic symptoms IN sickle cell disease (SCD); patient monitoring PREVENTS severe pain IN sickle cell disease (SCD); patient monitoring PREVENTS severe allergic symptoms IN sickle cell disease (SCD); management of pain TREATS severe pain IN sickle cell disease (SCD); management of severe allergic symptoms TREATS severe allergic symptoms IN sickle cell disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  management of severe allergic symptoms TREATS severe allergic symptoms IN sickle cell disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - evaluation of patient's prior history of IRRs to other monoclonal antibodies
      or medications
    - changes to crizanlizumab infusion rate
    - patient monitoring
    - management of pain
    - management of severe allergic symptoms
  symptoms:
    - severe pain
    - severe allergic symptoms
  chemicals:
    - crizanlizumab
  action_annotation_relationships:
    - subject: evaluation of patient's prior history of IRRs
      predicate: PREVENTS
      object: allergic symptoms
      qualifier: MONDO:0007374
      object_qualifier: severe
      subject_extension: other monoclonal antibodies or medications
      object_extension: severe
    - subject: crizanlizumab infusion rate
      predicate: PREVENTS
      object: HP:0012531
      qualifier: MONDO:0007374
      object_qualifier: severe
      subject_extension: crizanlizumab
      object_extension: severe
    - subject: crizanlizumab infusion rate
      predicate: PREVENTS
      object: severe allergic symptoms
      qualifier: MONDO:0011382
      subject_qualifier: changes to
      object_qualifier: severe
      subject_extension: crizanlizumab
    - subject: patient monitoring
      predicate: PREVENTS
      object: severe pain
      qualifier: MONDO:0011382
    - subject: <patient monitoring>
      predicate: <PREVENTS>
      object: <severe allergic symptoms>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <severe>
      subject_extension: <None>
      object_extension: <None>
    - subject: management of pain
      predicate: TREATS
      object: severe pain
      qualifier: MONDO:0007374
      object_qualifier: severe
    - subject: <management of severe allergic symptoms>
      predicate: <TREATS>
      object: <severe allergic symptoms>
      qualifier: MONDO:0007374
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <management of severe allergic symptoms>
      object_extension: <severe allergic symptoms>
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0001923
    label: Increased reticulocyte counts
  - id: CHEBI:80240
    label: Endothelin-1
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: HP:0001945
    label: fever
  - id: HP:0002754
    label: osteomyelitis
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000118
    label: immunization
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: MAXO:0009101
    label: Early intervention
  - id: HP:0000989
    label: pruritus
  - id: HP:0012393
    label: allergic reactions
  - id: HP:0012532
    label: chronic pain
  - id: HP:0007760
    label: SCD
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:6807
    label: Methadone
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:82557
    label: Treosulfan
  - id: MAXO:0000756
    label: Blood transfusions
  - id: HP:0012531
    label: Pain
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: MONDO:0005632
    label: Acute Chest Syndrome
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:49005
    label: Deferasirox
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0030157
    label: Flank pain
  - id: HP:0100749
    label: Chest pain
  - id: HP:0001878
    label: Hemolytic anemia
  - id: MONDO:0005570
    label: Hematological diseases
  - id: HP:0004444
    label: Spherocytosis
  - id: HP:0001028
    label: Hemangioma
  - id: HP:0001871
    label: Hematological diseases
  - id: MONDO:0017014
    label: children
  - id: HP:0030830
    label: crackles
  - id: HP:0002617
    label: Vasculopathy
  - id: MONDO:0005380
    label: Avascular necrosis
  - id: HP:0002829
    label: Joint pain
  - id: MAXO:0000586
    label: Invasive ventilation (not used)
  - id: MONDO:0006502
    label: Severe COVID-19 with acute respiratory distress syndrome (ARDS)
  - id: HP:0002094
    label: dyspnea
  - id: HP:0001873
    label: thrombocytopenia
  - id: MONDO:0003664
    label: Haemolytic anaemia
  - id: HP:0025435
    label: increased lactate dehydrogenase levels
  - id: HP:0011981
    label: pigment gallstones
  - id: HP:0001907
    label: thromboembolism
  - id: CHEBI:35341
    label: steroids
  - id: HP:0001890
    label: autoimmune haemolytic anaemia
  - id: MAXO:0000457
    label: Pain management
  - id: MAXO:0010030
    label: Bone marrow transplantation (BMT)
  - id: HP:0001297
    label: Stroke
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: HP:0001903
    label: Anemia
  - id: MONDO:0021200
    label: rare diseases
  - id: CHEBI:8093
    label: Phenylephrine
  - id: CHEBI:50858
    label: corticosteroids
  - id: HP:0002902
    label: Hyponatremia
  - id: CHEBI:26708
    label: Sodium
  - id: MAXO:0001175
    label: Liver transplantation
  - id: MAXO:0001394
    label: oral administration
  - id: MONDO:0004992
    label: Cancer
  - id: CHEBI:125354
    label: plerixafor
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000087
    label: Massage
  - id: MAXO:0000010
    label: Cognitive behavioral therapy
  - id: HP:0012432
    label: Chronic fatigue
  - id: HP:0000739
    label: Anxiety
  - id: HP:0000716
    label: Depression
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0000083
    label: Renal failure
  - id: HP:0004395
    label: Malnutrition
  - id: HP:0100806
    label: Sepsis
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0002878
    label: Respiratory failure
  - id: CHEBI:50443
    label: Autologous hematopoietic stem cell (HSC)-based gene therapy
  - id: MONDO:0005775
    label: Glucose-6-phosphate dehydrogenase deficiency
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:68554
    label: deferiprone
  - id: HP:0012649
    label: Increased inflammatory response
  - id: CHEBI:9570
    label: Thiotepa
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:3216
    label: Buprenorphine
  - id: HP:0001139
    label: <Transcranial doppler (TCD) monitoring>
  - id: CHEBI:204928
    label: cefotaxime
  - id: HP:0001727
    label: Thromboembolic stroke
  - id: CHEBI:5588
    label: Hemoglobin A (HbA)
  - id: HP:0003095
    label: septic arthritis
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0002013
    label: vomiting
  - id: HP:0001875
    label: neutropenia
  - id: HP:0012234
    label: agranulocytosis
  - id: CHEBI:4356
    label: deferoxamine
